Coaching patients on Achieving Cardiovascular Health (COACH): A Multicenter Randomized Trial in Patients with Coronary Heart Disease

Archives of Internal Medicine

Volumn 163, Issue 22, 2003, Pages 2775-2783

  Vale, Margarite J ^a,b   Jelinek, Michael V ^a,b   Best, James D ^a,b   Dart, Anthony M ^c   Grigg, Leeanne E ^a,d   Hare, David L ^a,e   Ho, Betty P ^f   Newman, Robert W ^a,g   McNeil, John J ^h  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e AUSTIN HEALTH   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g WESTERN HOSPITAL   (Australia)

^h MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIETITIAN; FEMALE; HEALTH; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NURSE; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALLIED HEALTH PERSONNEL; ANTILIPEMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; COUNSELING; FEMALE; FOLLOW-UP STUDIES; HEALTH BEHAVIOR; HUMANS; MALE; MIDDLE AGED; NURSING STAFF, HOSPITAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PATIENT-CENTERED CARE; PROGRAM EVALUATION; QUALITY OF LIFE; RISK FACTORS;

EID: 0345168132     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.22.2775     Document Type: Article

References (37)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
3. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
4. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease, part 2: short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
5. Joliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease (Cochrane review). In: The Cochrane Library. Oxford, England: Update Software; 2001:CD001800.
6. Bowker TJ, Clayton TC, Ingham JE, et al. A British Cardiac Society survey of the potential for secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart. 1996;75:334-342.
7. Holt ND, Johnson A, Davies A, et al. Secondary prevention in coronary artery disease: have we moved on from ASPIRE? Br J Cardiol. 1999;6:584-588.
8. EUROASPIRE II Steering Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357:995-1001.
9. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dysilpidaemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
10. Vale MJ, Jelinek MV, Best JD. How many patients with coronary heart disease are not achieving their risk factor targets? experience in Victoria 1996-1998 versus 1999-2000. Med J Aust. 2002;176:211-215.
11. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol. 1997;80(8B):45H-52H.
12. Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ. 1998;317:465-468.
13. Moher M, Yudkin P, Wright L, et al, for the Assessment of Implementation Strategies (ASSIST) Trial Collaborative Group. Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. BMJ. 2001;322:1-7.
14. McAlister FA, Lawson FME, Teo KK, et al. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ. 2001;323:957-962.
15. DeBusk RF, Houston Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction: MULTIFIT. Ann Intern Med. 1994;120:721-729.
16. Stagmo M, Westin L, Carlsson R, et al. Long-term effects on cholesterol levels and utilization of lipid-lowering drugs of a hospital-based programme for secondary prevention of coronary artery disease. J Cardiovasc Risk. 2001;8:243-248.
17. Robinson JG, Conroy C, Wickemeyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol (100 mg/dl). Am J Cardiol. 2000;85:305-308.
18. Senaratne MPJ, Griffiths J, Mooney D, et al. Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease. Am Heart J. 2001;142:975-981.
19. Heller RF, Knapp JC, Valenti LA, et al. Secondary prevention after acute myocardial infarction. Am J Cardiol. 1993;72:759-762.
20. Kirkman SM, Weinberger M, Landsman PB, et al. A telephone-delivered intervention for patients with NIDDM. Diabetes Care. 1994;17:840-846.
21. Cupples ME, McKnight A. Randomised controlled trial of health promotion in general practice for patients at high cardiovascular risk. BMJ. 1994;309:993-996.
22. Tooth LR, McKenna KT, Maas F. Pre-admission education/counselling for patients undergoing coronary angioplasty: impact on knowledge and risk factors. Aust N Z J Public Health. 1998;22:583-588.
23. Holt N, Johnson A, de Belder M. Patient empowerment in secondary prevention of coronary heart disease [letter]. Lancet. 2000;356:314.
24. Jolly K, Bradley F, Sharp S, et al. Randomised controlled trial of follow up in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). BMJ. 1999;318:706-715.
25. Vale MJ, Jelinek MV, Best JD, et al. Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the 'real world': randomized controlled trial. J Clin Epidemiol. 2002;55:245-252.
26. National Heart Foundation of Australia, The Cardiac Society of Australia and New Zealand. Lipid management guidelines 2001. Med J Aust. 2001;175(November 5 suppl):S57-S85.
27. National Heart Foundation of Australia Web site. Available at: www.heartfoundation.com.au. Accessed May 1999.
28. Zimmet P, Alberti G, de Courten MP. New classification and criteria for diabetes: moving the goalposts closer. Med J Aust. 1998;168:593-594.
29. Physical Status: The Use and Interpretation of Anthropometry: Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization; 1995. Technical report series 854.
30. Ireland P, Jolley D, Giles G, et al. Development of the Melbourne FFQ: a food frequency questionnaire for use in Australian prospective study involving an ethnically diverse cohort. Asia Pac J Clin Nutr. 1994;3:19-31.
31. Hare DL, Davis CR. Cardiac depression scale: validation of a new depression scale for cardiac patients. J Psychosom Res. 1996;40:379-386.
32. Spielberger CD, Gorsuch RL, Lushene RE. State-trait anxiety inventory. In: Stai Manual. Palo Alto, Calif: Consulting Psychologfsts Press Inc; 1970:3-8.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
34. StataCorp. Stata Statistical Software: Release 6.0. College Station, Tex: Stata Corp; 1999.
35. Moher D, Schulz KF, Altman DG, et al, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191-1194.
36. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3145-3421.
37. Jelinek MV, Vale MJ, Hare DL, Best JD. Coaching or cardiac rehabilitation? retrospective observations from the COACH study [abstract]. J Am Coll Cardiol. 2002;39(suppl):453B.